C
Catherine M. Kelly
Researcher at Mater Misericordiae University Hospital
Publications - 129
Citations - 3107
Catherine M. Kelly is an academic researcher from Mater Misericordiae University Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 107 publications receiving 2327 citations. Previous affiliations of Catherine M. Kelly include University of Texas MD Anderson Cancer Center & University College Dublin.
Papers
More filters
Journal ArticleDOI
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Catherine M. Kelly,David N. Juurlink,Tara Gomes,M. Duong-Hua,Kathleen I. Pritchard,Peter C. Austin,Lawrence Paszat +6 more
TL;DR: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetines can reduce or abolish the benefit of tamoxIFen in women with breast cancer.
Journal ArticleDOI
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Tiffany A. Traina,Tiffany A. Traina,Kathy D. Miller,Denise A. Yardley,Janice F. Eakle,Lee S. Schwartzberg,Joyce O'Shaughnessy,William J. Gradishar,Peter Schmid,Eric P. Winer,Catherine M. Kelly,Rita Nanda,Ayca Gucalp,Ahmad Awada,Laura García-Estévez,Maureen E. Trudeau,Joyce Steinberg,Hirdesh Uppal,Iulia Cristina Tudor,Amy C. Peterson,Javier Cortes +20 more
TL;DR: This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC and demonstrated clinical activity and was well tolerated in Patients with advanced AR- positive TNBC.
Journal ArticleDOI
Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Fatima Cardoso,Fatima Cardoso,John M. S. Bartlett,John M. S. Bartlett,Leen Slaets,C.H.M. van Deurzen,C.H.M. van Deurzen,E van Leeuwen-Stok,Peggy L. Porter,Peggy L. Porter,B. Linderholm,B. Linderholm,Ingrid Hedenfalk,Carolien P. Schröder,Carolien P. Schröder,John W.M. Martens,John W.M. Martens,Jane Bayani,C. J. van Asperen,C. J. van Asperen,Melissa Murray,Clifford A. Hudis,Clifford A. Hudis,Lavinia P. Middleton,Joanna Vermeij,Kevin Punie,Judith Fraser,M Nowaczyk,Isabel T. Rubio,Stefan Aebi,Catherine M. Kelly,Kathryn J. Ruddy,Eric P. Winer,Cecilia Nilsson,L. Dal Lago,Larissa A. Korde,Kim Benstead,Oliver Bogler,Theodora Goulioti,Aleksandra Peric,Saskia Litière,K Aalders,C. Poncet,Konstantinos Tryfonidis,Sharon H. Giordano +44 more
TL;DR: Better overall (OS) and recurrence-free survival (RFS) and a significant improvement over time was observed in age-corrected BC mortality and there was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade.
Journal ArticleDOI
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.
Filippo Montemurro,Suzette Delaloge,Carlos H. Barrios,Rachel Wuerstlein,Antonio Antón,Etienne Brain,Thomas Hatschek,Catherine M. Kelly,C. Pena-Murillo,M. Yilmaz,Margarita Donica,Peter M. Ellis,Peter M. Ellis +12 more
TL;DR: This exploratory analysis of patients with HER2-positive MBC and BM enrolled in a prospective clinical trial shows that T-DM1 is active and well-tolerated in this population and should be explored further in this setting.
Journal ArticleDOI
Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis
TL;DR: For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result.